logologo
QuantliQuantli

Precigen Inc

PGEN

NASDAQ

Biotechnology

$6.10

USD

-0.39 (-6.01%)

At close: Aug 14, 2026, 4:00 PM EDT

Market Cap $2.33B

Volume 7.9M

Price (USD)
Price (USD)

About Precigen Inc

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. The company is headquartered in Germantown, Maryland and currently employs 160 full-time employees. The company went IPO on 2013-08-08. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.

CEO

Dr. Helen Sabzevari

HQ

Germantown, MARYLAND, US

Founded

2013

Employees

160

Quantli Score

8.4

Outperform

Fin. Health

8.1

Profitability

7.6

Growth

9.0

Cash-Flow Q.

8.8

Key Metrics

6 metrics our research team weighs before forming a view on PGEN.

Based on Quantli research · SEC filings · as of Q2 2026

METRIC

VALUE

CHANGE

TREND (3Y)

Revenue Growth (TTM)

1875.0%

+1876.2 pp

Gross Margin (TTM)

90.7%

+91.4 pp

Operating Margin (TTM)

-46.1%

+2353.4 pp

Net Margin (TTM)

-184.0%

+2684.7 pp

ROE (TTM)

-361.9%

Free Cash Flow (TTM)

$-115.22M

Financial Snapshot

Full Financials

Revenue

$85.72M

+1875.0%

YoY

Gross Margin

91%

TTM

+13217.3%

YoY

Net Income

$-157.71M

-26.7%

YoY

Operating Cash Flow

$-114.17M

-72.3%

YoY

Key Statistics

Open

$6.32

Previous Close

$6.49

Day Range

$6.08 - $6.39

52 Week Range

$1.80 - $7.32

Volume

7.9M

Average Volume (10 Days)

7.1M

Dividend Yield

Valuation Measurement

Market Cap

$2.33B

P/E Ratio (TTM)

P/S Ratio (TTM)

27.23

Price / Book

53.57

Financial Highlights

Profit Margin

-184.0%

Return on Assets

-92.6%

Return on Equity

-361.9%

Revenue (TTM)

$85.72M

Net Income (TTM)

$-157.71M

Diluted EPS (TTM)

-$1.10

Total Cash (MRQ)

$16.33M

Levered FCF (TTM)

$-115.22M

Turn research into action

Knowing a stock is strong is the start. Knowing how to invest in it when you spot good research is good returns.

Swing Strategy

Buy support, sell on recovery.

Best for:

Risk-tolerant

Position Strategy

Ride market cycles. Patient hold.

Best for:

Patient investors

Trend Following

Enter on trend. Cut losses fast.

Best for:

Active traders

Go deeper on PGEN

Similar Stocks

AGIO

Agios Pharmaceuticals Inc

$33.56

+0.3%

ADMA

ADMA Biologics Inc

$9.47

+0.6%

ZBIO

Zenas Biopharma Inc

$29.51

+1.1%

PVLA

Palvella Therapeutics Inc

$156.13

-0.3%

STOK

Stoke Therapeutics Inc

$31.27

-0.1%

MLYS

Mineralys Therapeutics Inc

$25.64

-1.7%

VRDN

Viridian Therapeutics Inc

$22.08

+0.4%

GENB

Generate Biomedicines Inc

$15.64

+4.1%

Earnings Calendar

Next Earnings

Estimated Q3 Release

Nov 11

Est. EPS

Adjusted consensus estimate

$0.06

Analyst Consensus

Buy

Based on 1 analyst ratings

Avg Target: $18.00

(+195.1% upside)

High: $18.00 · Low: $18.00

Strong Buy

0%

Buy

100%

Hold

0%

Sell

0%

Strong Sell

0%

View full analyst ratings